CrkII belongs to the adaptor protein family that plays a crucial role in signal transduction. In order to better understand the biological functions of CrkII, we focused on the regulation of gene expression by CrkII. Various transcriptional control elements were examined for their activation by CrkII-expression, and we found that CrkII selectively activates the serum response element (SRE), a transcriptional control element of immediate-early genes. This SRE activation induced by CrkII-overexpression was mediated by the serum response factor (SRF) via Rho. Indeed, we confirmed that the amount of activated Rho was increased in the CrkII-expressing cells. Moreover, we showed that when overexpressed, CrkII induces the cellular transformation of NIH 3T3 cells and that a dominant negative mutant of Rho suppresses this transformation, strongly suggesting that activation of Rho is essential for the transforming activity by CrkII. Furthermore, we also found that CrkII and Ga12, a member of the heterotrimeric G proteins, synergistically activates Rho as well as the SRF, and that an SH3 mutant of CrkII can inhibit the Ga12-induced activation of SRF. These results strongly suggest that CrkII is involved in the activation of Rho and SRF by Ga12. Our study provides strong evidence that Rho activation plays a crucial role in CrkII-mediated signals to induce gene expression and cellular transformation.
Introduction
The Crk family of adaptor proteins was originally identified as the oncogene product of the avian sarcoma virus CT10, v-Crk (Mayer et al., 1988) . The mammalian cellular homologues of v-Crk, including CrkI, CrkII, and closely related CrkL, have subsequently been identified (Matsuda et al., 1992; Reichman et al., 1992; ten Hoeve et al., 1993) . Crk family proteins are composed primarily of the Src homology (SH) 2 and SH3 domains, and the widely expressed CrkII has an Nterminal SH2 domain and two SH3 domains (Matsuda et al., 1992; Reichman et al., 1992) . The most interesting feature of the Crk family is its ability to induce many interesting biological activities despite the lack of an enzymatic domain. For example, v-Crk induces oncogenic transformation of chicken embryo fibroblasts (CEF) and the elevation of tyrosine phosphorylation levels of several proteins (Birge et al., 1996; Feller, 2001) . CrkL, which has a similar structure to CrkII, has also been reported to induce the anchorage independent growth of Rat1 cells. Even though cellular CrkII has not been reported to have oncogenic potential, it has been shown to regulate several biological activities, including mitogenesis and reorganization of the cytoskeleton (Klemke et al., 1998; Nakashima et al., 1999; Cho and Klemke, 2000; Gumienny et al., 2001) . To date, v-Crk studies have reported its activation of several signaling pathways, such as the JNK, PI3K/AKT, and Rho small GTPase pathways (Tanaka et al., 1997; Altun-Gultekin et al., 1998; Akagi et al., 2000) , however, little is known about the transcriptional factors which are affected by Crk downstream in its signaling pathways. In this study, therefore, we initially asked the question as to whether or not CrkII is involved in the regulation of gene expression, and analyzed the molecular events affected or controlled by the expression of cellular CrkII.
Various oncogenic signals and mitogen-stimulated signals result in the transcriptional activation of immediate-early genes (IEGs), such as c-fos and Egr-1. IEGs play a critical role in mitogenesis and contribute to cellular transformation (Greenberg and Ziff, 1984; Lau and Nathans, 1985; Herschman, 1991; Meijne et al., 1997) . Several IEGs contain a common cis-acting transcriptional control element, termed the serum response element (SRE) (Herschman, 1991; Treisman, 1995) . The SRE is essential for the transcriptional activation of IEGs by a number of growth stimulating factors acting on tyrosine kinases and G-proteincoupled receptors (GPCRs) (Treisman, 1995) . In addition, the SRE can be activated in the absence of growth factor stimulation by oncogene products, such as v-Ras, v-Src, and v-Raf (Treisman, 1995) . Two c-fos SREbinding proteins, the serum response factor (SRF) and the ternary complex factor (TCF) of the Ets family have been shown to be important for SRE-mediated gene expression. TCFs are phosphorylated and transactivated in response to activation of the mitogen-activated protein kinases (MAPKs) signaling pathway (Gille et al., 1992; Treisman, 1996) . In contrast, SRF activity is regulated by a signaling pathway in which the Rho family of small GTPases are involved (Hill et al., 1995) .
This pathway can stimulate SRF-mediated transcription through a TCF-independent mechanism (Hill and Treisman, 1995; Hill et al., 1995) . For example, some GPCR-mediated stimuli, like lysophosphatidic acid, selectively induce Rho-dependent SRF activation without significant TCF activation (Hill et al., 1995) . Moreover, the constitutively active forms of the a subunits of the Gq and G12 class of heterotrimeric G proteins have been reported to activate SRF via Rho activation (Fromm et al., 1997; Mao et al., 1998b,c; Fukuhara et al., 1999) , indicating that Rho activation is essential for transmission of these kinds of signals to the nucleus via SRF activation (Hill et al., 1995) .
By using reporter gene assays for various transcriptional control elements, here we show that CrkIIexpression results in selective transcriptional activation mediated by the SRE. This SRE activation by CrkII occurs through an SRF-dependent pathway via Rho activation. Moreover, we found that CrkII-expression results in cellular transformation and that Rho activation is required for this transforming activity by CrkII. In addition, we also provide evidence that CrkII is likely to be involved in the Rho activation pathway induced by the heterotrimeric G protein subunit Ga12. Therefore, we have here characterized a novel CrkII-mediated signal that potently activates Rho, which consequently regulates transcriptional activation as well as cellular transformation.
Results

CrkII activates SRE-mediated gene expression through SRF activation
To assess whether expression of CrkII activates intracellular signaling pathways leading to transcriptional activation, we used reporter plasmids carrying the luciferase gene under the control of various well-defined transcriptional control elements, which are known to be regulated by many signaling pathways. The reporter plasmids pSRE-luc, pMyc-luc, pAP-1-luc, and pNF-kBluc contain the CArG box of the c-fos SRE (Akagi et al., 1997) , the Myc-Max heterodimer binding sequence (CACGTG) (Ayer et al., 1996) , the AP-1 binding TRE elements, and the NF-kB site from the murine Ig k gene (Akagi et al., 1997) , respectively. NIH 3T3 cells were transiently cotransfected with the CrkII expression vector and each of these luciferase reporter constructs. These luciferase reporter assays showed that SRE-mediated gene transcription was most prominently activated by CrkII (Figure 1a) . Although Crk has been reported to activate the JNK pathway (Tanaka et al., 1997; Dolfi et al., 1998) , which is well known to regulate AP-1 transcription activity (Davis, 2000) , AP-1 activation was only slightly induced by CrkII-expression compared with SRE activation (Figure 1a ). pMyc-luc and pNF-kB-luc were also activated only slightly. From these results, we focused on the signal induced by the overexpressed CrkII to the SRE as critical molecular events downstream of CrkII, which can regulate gene transcription.
The SRE-mediated gene expression by CrkII was almost completely blocked by the mutation in the SRE that prevents SRF binding (Figure 1b ). This implies that CrkII activates the SRE through an SRF-dependent mechanism. To further confirm the SRF as the target of CrkII in signaling to the SRE, we used another reporter plasmid containing an altered c-fos SRE, SRE.L, which binds only to the SRF, and not to TCF, and has been shown to be regulated by SRF independently of TCF (Hill et al., 1995) . As shown in Figure 1c , we found that expression of CrkII gave a 10-fold increase in the SRE.L-luciferase activity. As a positive control, we consistently confirmed that constitutively activated RhoA (RhoV14) could also induce the SRE.L-luciferase activity under the same experimental condition ( Figure 1c) . Next, to examine the contributions of each SH2 and SH3 domain of CrkII in its transcriptional activity, an SH2-deficient mutant (R38 K), and two SH3-deficient mutants (W169 K and W275 K) were transiently transfected into NIH3T3 cells (Figure 1d ). We found that all of the three SH domains were required for complete SRF activation by CrkII (Figure 1e ). Taken together, these results indicate that CrkII can activate SRE-mediated gene expression through an SRF-dependent pathway in NIH 3T3 cells.
CrkII activation of SRF is mediated by Rho
Since it has been reported that the Rho family of small G proteins, Rho, Cdc42, and Rac induce SRF activation (Hill et al., 1995) , we investigated the Rho familymediated signaling pathways in CrkII-overexpressing cells. We examined the effect of the simultaneous expression of CrkII and the Clostridium botulinum C3 transferase, which specifically ADP-ribosylates and deactivates Rho proteins but not Cdc42 nor Rac (Hill et al., 1995) . As shown in Figure 2a , the coexpression of C3 almost completely abolished the SRF-mediated gene transcription induced by CrkII. Consistent with previous studies, C3 prevented the induction of SRFmediated gene transcription by constitutively activated RhoA (RhoV14), but neither by activated Cdc42 (Cdc42V12), activated Rac1 (RacV12) nor by v-Src, which has been demonstrated to activate SRF both through Cdc42 and Rac1 (Mao et al., 1998a) , suggesting that C3 specifically prevents the Rho-mediated activation pathway (Figure 2a ). In addition, coexpression of a dominant inhibitory mutant of Rho (Rho N19) (Khosravi-Far et al., 1995) also suppressed SRF activation by CrkII, but not by activated RacV12 (Figure 2b ). These results confirmed that CrkII expression activates Rho, and also clearly demonstrated that Rho activation is required for SRF activation induced by CrkII-overexpression.
CrkII-expression activates Rho
To assess more directly the activation of the endogenous Rho protein by CrkII, we used a GST-fusion protein of the Rho-binding domain of Rhotekin (GST-RBD) to affinity-precipitate activated GTP-loaded Rho from 293 T cell lysates (Ren et al., 1999) . We confirmed that the overexpression of CrkII also activated SRFmediated gene transcription in 293 T cells (data not shown). As shown in Figure 3a , the amount of activated Rho was markedly increased in the CrkII transfected cells as well as the serum stimulated cells or cells transfected with the activated form of the Ga12 heterotrimeric G-protein a subunit (Ga12QL) taken as the positive control. Moreover, in accordance with SRF activity, both the SH2 and SH3 mutants also had less ability to induce Rho activation ( Figure 3b ) compared with wild-type CrkII. These results directly showed that the overexpression of CrkII induced the activation of the Rho small G-protein.
CrkII transforms NIH 3T3 cells
As described above, we demonstrated that the overexpression of CrkII is sufficient to activate SRE-mediated gene expression. This increase in SRE-mediated gene expression has been induced by many oncogene products such as v-Ras, v-Src, and v-Raf. Moreover, we observed that NIH 3T3 cells infected with a retrovirus expressing CrkII showed morphologic alteration in monolayer culture ( Figure 4a ) and an increased acidification of the culture media, a frequent finding with transformed cells (data not shown). These observations prompted us to reexamine the oncogenic potential of CrkII, even though a previous study has reported that CrkII failed to transform 3Y1 cells (Matsuda et al., 1992) . We performed the softagar colony formation assay with NIH 3T3 cells by infection with a retrovirus carrying the CrkII gene to test its transforming activity. Surprisingly, we found that CrkII infected NIH 3T3 cells formed colonies in soft agar, while no colonies were found in cells infected with the control retrovirus ( Figure 4b ). Overexpression of Grb2, which is another adaptor protein composed of SH2 and SH3 domains, did not induce the morphologic transformation and the soft-agar colony formation activity, even though its expression level was nearly same as CrkII (Figure 4 ). This result clearly indicated that overexpression of CrkII induces cellular transformation in NIH 3T3 cells. Using the same retroviral vector system, we observed that overexpressed CrkII also induced anchorage independent growth of several other cell lines derived from mouse embryo fibroblasts (data not shown).
Rho activation is required for cellular transformation induced by overexpressed CrkII
We also compared the ability of the overexpressed CrkII mutants to induce the anchorage-independent growth of NIH 3T3 cells. As shown in Figure 5 , we found that all of the three SH domains are necessary for complete transformation by CrkII, in accordance with both SRF activation ( Figure 1e ) and Rho activation ( Figure 3b ). These results strongly suggest that the activation of SRF and Rho play a role in cellular transformation induced by the overexpressed CrkII.
Furthermore, when we simultaneously infected retroviruses expressing CrkII and a dominant inhibitory mutant of RhoN19 into NIH 3T3 cells, colony formation of NIH 3T3 cells by CrkII was completely suppressed ( Figure 6 ). In contrast, a dominant inhibi- Figure 3 (a) CrkII increases the amount of GTP-Rho. 293 T cells were transfected with constructs expressing b-galactosidase (lacZ), CrkII, and activated Ga12Q229L (Ga12QL). After serum starvation for 24 h, cells were lysed, and the lysates were incubated with GST-RBD glutathione beads. After washing, the bound activated Rho proteins were analyzed by immunoblotting using an antiRhoA antibody (upper panel). As a positive control, cells transfected with LacZ were treated with 15% serum for 10 min before the assay (LacZ/FCS). The level of endogenous Rho in the cell lysates was analysed by immunoblotting using the anti-RhoA antibody (lower panel). The results are the representatives of three independent experiments. (b) Regulation of Rho activity by CrkII mutants. 293 T cells were transfected with constructs expressing CrkII and its mutants as indicated. After serum starvation for 24 h, cells were lysed, and the lysates were incubated with GST-RBD glutathione beads. After washing, the bound proteins were analysed as in (a). The expression levels of RhoA and the CrkII mutants in the lysates were analysed by immunoblotting using the appropriate antibody . The empty vector was used to make the total amount of DNA in all transfections equal. After serum starvation for 24 h, cells were lysed, and b-galactosidase and luciferase activities were determined as in Figure 1 Crk-mediated SRF activation and transformation via Rho T Iwahara et al tory mutant of Rac1 (RacN17) (Khosravi-Far et al., 1995) displayed only partially suppressing colony formation by CrkII (Figure 6 ). These results clearly show that CrkII induces cellular transformation in a Rho-dependent manner (and to a lesser extent in a Racdependent), and strongly suggests that Rho activation is the critical step for CrkII to induce oncogenic activity.
CrkII enhances Ga12-stimulated activation of Rho and SRF Our finding that CrkII induces the activation of Rho to regulate SRF-mediated gene transcription raises another interesting possibility that CrkII might be physiologically implicated in the cellular signaling pathway leading to the activation of Rho and SRF. In this context, we have considered the signals mediated by the heterotrimeric G-protein Ga12 as a candidate upstream signal of CrkII, since it is well known that SRF-mediated gene transcription is selectively activated by agonists of some GPCRs through a Rho-dependent pathway without significant TCF activation, primarily mediated by the Ga12 class (Hill et al., 1995; Fromm et al., 1997; Mao et al., 1998b) .
To test this possibility, we first examined the effect of CrkII expression on the Ga12-induced activation of SRF. Coexpression of Ga12 with CrkII markedly increased the level of the SRE.L-luciferase activity over the level observed with the expression of either the G-protein or CrkII alone, showing the synergistic activation of SRF by CrkII and Ga12 (Figure 7a) . Similarly, the constitutively activated form of Ga12 Moreover, using the GST-RBD pull-down assay, we demonstrated that the amount of activated GTP-loaded Rho was dramatically increased in 293 T cells cotransfected with Ga12QL and CrkII compared to that in cells transfected with the G protein or CrkII cDNA alone (Figure 7b) , showing the synergistic effect of these proteins in the activation of Rho. These results clearly indicate that CrkII synergizes with Ga12 in Rho activation to mediate SRF activation.
The CrkII mutant inhibits Ga12-induced signaling to the SRF To identify the domains of CrkII that are required for this synergistic effect, we analysed the effect of the expression of CrkII mutants on SRF activation by Ga12. As shown in Figure 8a , cotransfection of the SH2 mutant (CrkR38 K), or two SH3 mutants (CrkW169 K and CrkW275 K) with Ga12 showed less synergistic effects on Ga12-induced SRF activation, compared with wild-type CrkII. Thus, all the SH-domains of CrkII are required for complete cooperation in SRF activation with Ga12. More interestingly, we found that coexpression of the amino-terminal SH3 mutant (CrkW169 K) significantly reduced the Ga12-induced activation of SRF (Figure 8a ). In addition, this inhibitory effect of CrkW169 K was dependent on the amounts of transfected DNA (Figure 8b ). These results suggest that CrkII plays a role in the activation of SRF by Ga12.
In NIH 3T3 cells, it has been shown that not only the G12 family, but also the Gq family can activate SRFmediated gene transcription in a Rho-dependent manner (Mao et al., 1998b,c) . Consistent with this observation, CrkII activates Rho in synergy with Ga12. 293 T cells were cotransfected with 2 mg of b-galactosidase (LacZ), or the CrkII expression plasmid in the presence or absence of 2 mg of the Ga12QL expression plasmid. The b-galactosidase expression plasmid was used to make the total amount of DNA in all transfections equal. After serum starvation for 24 h, cells were lysed, and the lysates were incubated with GST-RBD glutathione beads. After washing, the bound active Rho proteins were analysed as in Figure 3 . The expression levels of RhoA, CrkII, and Ga12 in the lysates were analysed by immunoblotting using the appropriate antibody Crk-mediated SRF activation and transformation via Rho T Iwahara et al we confirmed that the constitutively activated form of a member of the Gq family, Ga11QL activates SRFmediated gene transcription and that the Rho inhibitor C3 completely blocks it under our experimental conditions (Figure 9a ). In order to verify the specificity of the inhibitory effects of CrkW169 K on the signaling pathway leading to SRF activation, we expressed constitutively activated forms of Ga11 (Ga11QL) and Ga12 (Ga12QL) in the presence or absence of CrkW169 K. As shown in Figure 9b , the SRF activation caused by Ga12QL was readily suppressed by coexpression of CrkW169 K. On the contrary, the activation of SRFmediated gene transcription induced by constitutively activated Ga11QL was not inhibited by CrkW169 K at all, showing the specificity of the inhibitory effect of CrkW 169 K. Considering that both Ga11QL and Ga12QL activate SRF through Rho (Figure 9a) , the different inhibitory effects of CrkW169 K on the Ga11QL-and the Ga12QL-induced SRF activation suggest that CrkII is likely to lie downstream of Ga12 but upstream of Rho. These results may imply that there is a CrkII-mediated pathway in the Ga12-induced activation of Rho, eventually inducing SRF-mediated gene expression. There are several reports demonstrating that Crk plays some role in the regulation of Rho during stress fiber formation. For example, expression of v-Crk was shown to regulate actin cytoskeleton organization by activating the C3-sensitive pathway, (Altun-Gultekin et al., 1998; Tsuda et al., 2002) and microinjection of an anti-Crk antibody and GST-Crk-SH2 or -SH3 proteins induced the collapse of stress fibers (Nakashima et al., 1999) , suggesting a general role of the Crk family in regulating Rho activity. These findings are consistent with our idea that Rho activation may be a crucial regulatory mechanism downstream of CrkII.
CrkII induces cellular transformation via Rho
In this report, we show that the expression of CrkII leads to anchorage-independent growth of NIH 3T3 cells, implying that not only v-Crk but CrkII also has oncogenic potential. A previous study has reported however, that 3Y1 cell lines expressing CrkII did not transform (Matsuda et al., 1992) . Although the reason for this discrepancy is not immediately clear, it seems most likely to be due to a difference in experimental conditions. In contrast to the previous study in which four independent CrkII-expressing cell clones were established and subjected to analysis, we used a bulk cell population expressing CrkII introduced by a highly efficient retroviral vector system (Akagi et al., 2000; Morita et al., 2000) . We believe that our system enabled us to better examine the representative biological activity induced by CrkII-expression. Since Senechal et al. (1996 Senechal et al. ( , 1998 ) also reported the transformation of Rat1 cells by CrkL using a similar retroviral vector system, transforming activity seems to be a general interesting feature of the Crk family adaptor proteins.
We observed that CrkII transformed NIH 3T3 cell populations contained pronounced extended cells, similar to those reported with transformed cells by activated RhoA and a specific GEF for Rho (Zheng et al., 1995; Lin et al., 1999) . Using a dominant negative Rho mutant (RhoN19), we have here demonstrated that Rho activity is required for the transforming activity of CrkII. In fact, expression of a constitutively activated form of RhoA is sufficient to induce anchorage independent growth of NIH 3T3 cells (Khosravi-Far et al., 1995) . Recently, Rho has been implicated in the downregulation of the Cdk inhibitors p21 cip1 and p27 kip1 in the midto late-G1 phase (Olson et al., 1998; Hu et al., 1999) , and has been shown to be required for sustained ERK activation associated with cyclin D1-expression in the mid-G1 phase (Welsh et al., 2001) . Therefore, these Rho-mediated regulations of cell cycle progression might be involved in anchorage-independent cell growth induced by CrkII-overexpression. However, other signaling routes also appear to be involved in the transformation by overexpressed CrkII since we have previously demonstrated that the phosphoinositide 3-kinase (PI3 K)/AKT pathway is constitutively activated in v-Crk-transformed chicken embryo fibroblasts and the inhibition of PI3 K blocks v-Crk-induced transformation (Akagi et al., 2000) . Similarly, another group has reported that v-Crk enhances cell survival, and inhibition of PI3 K reduces this activity (Stam et al., 2001) . Furthermore, the coupling of CrkII and p130
Cas has been reported to be involved in the suppression of apoptosis in a three-dimensional collagen matrix (Cho and Klemke, 2000) . Considering these data, it can be speculated that the Rho-mediated regulation of cell cycle progression and the PI3K/AKT-mediated activation of the survival signal may coordinately contribute to the anchorage-independent growth induced by CrkII.
Although several recent studies have reported the CrkII involvement in Rac activation pathway, a dominant negative RacN17 displayed only a modest inhibitory effect on the CrkII-induced transformation while RhoN19 could completely suppress (Figure 6 ). Since the CrkII-induced SRF activation was efficiently blocked by C3 or RhoN19 which could not suppress the RacV12-induced SRF activation (Figure 2 ), Rac may not play a major role in cell transformation induced by CrkII-overexpression. Considering the previous reports that RacN17 displays inhibitory effects on CrkII-related cell migration (Klemke et al., 1998; Cheresh et al., 1999) , RacN17 may affect the mobility or the morphological changes in CrkII-transformed cells.
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Roles of CrkII in the signal pathway leading to Rho and SRF activation
The observation that CrkII activates the SRE through a pathway independent of the TCF raised the possibility that CrkII may be involved in the G-protein-induced SRF activation pathway because c-fos SRE activation induced by stimulation through heterotrimeric G proteins, like stimulation with LPA or ALF 4 requires SRF but is independent of TCF binding (Hill and Treisman, 1995; Hill et al., 1995) . In contrast, activation of the SRE by growth factors, like PDGF, EGF, and colony-stimulating factor-1, requires TCF binding via activation of MAPK cascades (Gille et al., 1992; Johansen and Prywes, 1994; Treisman, 1994) . In this study, we provide evidence indicating that CrkII is involved in the activation of Rho and SRF induced by the Ga12 subunit of heterotrimeric G proteins. Coexpression of CrkII and Ga12 acted synergistically in the activation of Rho and SRF, and an SH3 mutant of CrkII was able to inhibit the Ga12-mediated SRF activation. Consistent with our idea, it has been reported that Crk forms a complex with its binding partners in response to stimuli mediated by heterotrimeric G-proteins, including LPA stimulation, which acts predominantly through the G12 family (Casamassima and Rozengurt, 1997; Posern et al., 2000) . Taken together, we conclude that CrkII is involved in the regulation of Rho and SRF by Ga12.
Constitutively activated Ga12QL has exhibited strong transforming potential in rodent fibroblasts (Chan et al., 1993; Jiang et al., 1993; Xu et al., 1993; VoynoYasenetskaya et al., 1994) . Coexpression of CrkII and Ga12QL increased the number of colonies in soft agar over the number observed with the expression of either CrkII or the G protein alone (data not shown; an average of 10-fold higher than CrkII, 1.5-fold higher than Ga12QL). However, we could not obtain the evidence for inhibition of the Ga12QL-induced colony formation by CrkW169 K, which could partially block the Ga12QL-induced SRF activation. While Rho activation has been shown to be involved in the Ga12-induced cell transformation (Fromm et al., 1997; Tolkacheva et al., 1997) , several studies have also shown that Ga12 induces other proliferative pathways, for example, activation of JNKs (Prasad et al., 1995; Collins et al., 1996; Voyno-Yasenetskaya et al., 1996) , and activation of AP-1 complex (Collins et al., 1996) . Interestingly, Tolkacheva et al. (1997) have reported that the Ga12-induced mitogenesis is not significantly perturbed by Rho inhibition with C3. Moreover, RhoN19 has been reported to only partially suppress transformation by Ga12QL, while RacN17 or RasN17 can strongly suppress (Tolkacheva et al., 1997; Zohn et al., 2000) . From these reports, we consider that the blocking of the Crk-Rho pathway may not be sufficient for complete inhibition of the transformation by Ga12QL.
The mechanism of Rho activation by CrkII and the involvement of CrkII in Ga12-mediated Rho activation need further studies. We found that all of the three SH2 and SH3 domains of CrkII are required for its activation of Rho and SRF, and its transformation of NIH 3T3 cells. The amino-terminal SH3 domain seems to be the most important for the regulation of these activities since expression of the mutant form of this domain significantly blocked Ga12-mediated Rho activation. This domain has been found to bind to regulators of the small GTPases, such as C3G and DOCK180 (Feller, 2001) . C3G is a guanine nucleotide exchange factor (GEF) for Rap1 (Gotoh et al., 1995) , and DOCK180 can bind and activate Rac1 GTPase (Kiyokawa et al., 1998; Nolan et al., 1998) . Thus, although none of the binding partners of CrkII have been shown to regulate Rho activation so far, there is a possibility that some molecules, which regulate Rho activity directly or indirectly, may associate with this domain. The finding that the C-terminal SH3 domain of CrkII is required for transformation is interesting. Although a very recent study has reported that this C-terminal region contains a binding site for the nuclear export factor Crm1, the function of this SH3 domain is poorly understood (Smith et al., 2002) . Similar to our results, the Cterminal SH3 domain of CrkL has also been reported to be required for its transforming activity (Senechal et al., 1998) . In addition, mutations in this SH3 domain have been reported to disrupt EGF-induced Ras activation in NRK cells (Kizaka-Kondoh et al., 1996) . Taken together, these findings indicate that this C-terminal SH3 domain plays an important role(s) in exerting the function of CrkII.
Several recent studies have reported that the G12 family, Ga12 and Ga13, directly regulate Rho GEFs and thereby trigger Rho activation Kozasa et al., 1998; Fukuhara et al., 1999 Fukuhara et al., , 2000 . However, tyrosine kinases also seem to be important in regulation of the G12 family-mediated Rho activation (Gohla et al., 1998; Katoh et al., 1998; Chikumi et al., 2002; Kranenburg et al., 1999) . For instance, the EGF receptor, Tec family, Src family, Pyk2, FAK, and Csk tyrosine kinases have all been reported to be involved in G12 family-mediated Rho activation (Gohla et al., 1998; Mao et al., 1998a; Nagao et al., 1999; Shi et al., 2000; Chikumi et al., 2002; Lowry et al., 2002) . In addition, the Vav family of GEF for Rho family has been known to be regulated in its activity by tyrosine phosphorylation (Aghazadeh et al., 2000) , while p190 RhoGAP, a GTPase-activating protein for Rho, has been shown to be phosphorylated and activated by Src (Chang et al., 1995; Arthur et al., 2000; Brouns et al., 2001; Haskell et al., 2001) . Considering that CrkII is known to mediate many signals from the tyrosine kinases (Feller, 2001) , it is also possible that the tyrosine kinases or tyrosine phosphorylated molecules may be involved in this system. Moreover, it is interesting that there are different requirements for tyrosine kinase activation in the Ga12-, the Ga13-, and the Gaq-induced Rho signaling (Gohla et al., 1998; Katoh et al., 1998; Shi et al., 2000) . The different inhibitory effects exerted by the Crk SH3 mutant on the signal mediated by each of the two G proteins, Ga12 and Ga11, (Figure 9b ) may be attributed to this difference in tyrosine kinase requirement. Recently, we found that CrkII associated mole-cules are hyper-tyrosine phosphorylated in the presence of constitutively activated Ga12 (our unpublished data). Further characterization of such CrkII associated molecules that specifically respond to Ga12 will reveal the mechanism of crosstalk among Ga12, Rho exchange factors, and tyrosine kinases, which promote the activation of Rho.
Materials and methods
Plasmids and antibodies
pcDNA3-CrkIIwt, and the SH2-and two SH3-deficient mutants of CrkII (R38 K, W169 K and W275 K) were previously described (Shishido et al., 2001) . R38 K is an SH2 point mutant in which the Arg at position 38 has been changed to Lys. The N-and C-terminal SH3 domain mutations were single-amino-acid changes of Trp to Lys at positions 169 (W169 K) and 275 (W275 K), respectively. Flag-tagged versions of the wild-type and the CrkII mutants were created by PCR and subcloned into the murine retroviral vector pBabePuro (Morgenstern and Land, 1990) . Expression plasmids for the C3 exoenzyme, and the wild type and constitutively active forms of Ga12 and Ga11 were kindly provided by S Narumiya (Kyoto University) and H Itoh (Nara Institute of Science and Technology), respectively. cDNAs of RhoA V14, RhoA N19, Rac1 V12, Rac1 N17, and Cdc42 V12 were kindly provided by A Hall (University College London). The RhoA N19 and Rac1 N17 cDNAs were subcloned into the murine retroviral vector pCXbsr (Akagi et al., 2000) . pSRE-luc, pSRE-mSRFluc, and pNF-kB-luc were previously described (Fujii et al., 1995; Akagi et al., 1997) . pMyc-luc, which was constructed by inserting four copies of the canonical Myc-Max binding site (CACGTG) into pGL2-pro (Promega) (Ayer et al., 1996) , was kindly provided by RN Eisenman (Fred Hutchinson Cancer Research Center). pAP-1-luc, which contains two copies of the TRE element in pGL2 (Promega), was kindly provided by T Ouchi (Mount Sinai Medical School). The reporter gene plasmid SRE.L was synthesized exactly as described in Hill et al. (1995) and two copies of the SRE.L sequence were inserted into the pGL3-promoter vector (Promega). To make the GST-RBD construct, the coding sequence for the RBD was amplified by PCR from a mouse brain cDNA library (Clontech) and cloned into the pGEX-2 T vector (Clontech) as described in Ren et al. (1999) . The following antibodies were purchased: anti-Crk monoclonal antibody (Transduction Laboratories); anti-RhoA monoclonal antibody, anti-HA rabbit polyclonal antibodies, and anti-Ga12 rabbit polyclonal antibodies (Santa Cruz Biotechnology); and anti-FLAG rabbit polyclonal antibodies (Sigma).
Cell culture
NIH 3T3 fibroblasts were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 5% calf serum and antibiotics at 371C in 5% CO 2 . Human embryonic kidney (HEK) 293 T cells were maintained in DMEM containing 10% fetal calf serum and antibiotics at 371C in 5% CO 2 .
Soft-agar colony formation assay
Retrovirus stocks were created by transient transfection of Plat-E cells (Morita et al., 2000) using FuGENE 6 (Roche Diagnostics Co.), and NIH 3T3 cells were infected with these retrovirus stocks as described previously (Akagi et al., 2000) . At 2 days after the infection, drug selection of infected cells was started, and the selected populations were used for the following experiments. For the soft-agar colony formation assay, infected cells were plated into a soft-agar matrix as previously described (Akagi et al., 2000) . Plates were incubated at 371C in 5% CO 2 for 3-4 weeks until colonies were formed. Colonies were stained with 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) as described (Alley et al., 1991) and photographs of the stained colonies were taken.
Immunoblot analysis
Cells were lysed in ice-cold lysis buffer (10 mm Tris, pH 7.6, 1% NP-40, 150 mm NaCl, 10% glycerol, 2.5 mm EDTA, 50 mm NaF, 2 mm Na 3 VO 4 , 20 mm sodium pyrophosphate, 10 mg/ml each of leupeptin and aprotinin, and 1 mm PMSF). Lysates were cleared by centrifugation (14 000 g for 20 min) and adjusted to equal protein concentrations. The samples were subjected to SDS-PAGE and transferred to an Immobilon membrane (Millipore). The membrane was then blocked and incubated with the indicated antibodies. Enhanced chemiluminescence (ECLPlus) reagents (Amersham) were used for detection as indicated by the manufacturer.
Luciferase assay
NIH 3T3 cells were seeded onto 24-well plates the day before transfection. Cells were transfected with each luciferase reporter plasmid as well as control b-galactosidase carried by the pEF-BOS expression vector (Mizushima and Nagata, 1990) using FuGENE 6, as instructed by the manufacturer. At 3 h after the transfection, serum starvation was started by switching to a culture medium containing 0.25% calf serum. Cell lysates were prepared 12 or 24 h later for luciferase assays. Cell lysates were tested for b-galactosidase activity using chlorophenolred-b-d-galactopyranoside (CPRG) as the substrate, and tested for luciferase activity using a luciferase substrate (Promega) by measuring luminescence intensity. Luminescence intensity was normalized against the b-galactosidase activity of a control reporter gene.
Affinity-precipitation of cellular GTP-Rho
Bacterially expressed GST-RBD was purified using glutathione-coupled Sepharose 4B beads (Pharmacia Biotech). The transfected 293 T cells were washed with ice-cold PBS, and lysis buffer (50 mm Tris, pH 7.4, 1% NP-40, 100 mm NaCl, 10% glycerol, 5 mm MgCl 2 , 1 mm EDTA, 50 mm NaF, 1 mm Na 3 VO 4 , 10 mg/ml each of leupeptin and aprotinin, and 1 mm PMSF) was added. Cell lysates were clarified by centrifugation and equal volumes of lysates were incubated with the GST-RBD (30 mg) beads at 41C for 40 min. The beads were washed three times with lysis buffer. The samples were fractionated on 12% SDS-PAGE and transferred to an Immobilon membrane. Bound Rho proteins were detected by immunoblotting using a monoclonal antibody against RhoA.
